Estrogen action in mood and neurodegenerative disorders: Estrogenic compounds with selective properties - The next generation of therapeutics

Marie K. Österlund, Michael Robin Witt, Jan Åke Gustafsson

Research output: Contribution to journalReview articlepeer-review

48 Scopus citations

Abstract

In this review, estrogenic effects in depression, anxiety, and neurodegenerative disorders are summarized. Moreover, preclinical findings from in vitro and animal models are discussed. There is a correlation between decreased estrogen levels (e.g., premenstrually, during the postpartum period, and perimenopausally) and increased anxiety and depressive symptoms. Several studies show beneficial effects of estrogen treatment in women with anxiety and depressive symptoms. Recent data indicate that the estrogen receptor (ER) β appears to be a major mediator of estrogenic effects in depression and anxiety. Additionally, both preclinical and clinical findings suggest that activation of estrogen receptors have an important role in neuroprotective and neurodegenerative processes in the mammalian central nervous system (CNS).

Original languageEnglish (US)
Pages (from-to)235-241
Number of pages7
JournalEndocrine
Volume28
Issue number3
DOIs
StatePublished - Dec 2005

Keywords

  • 17β-estradiol
  • Affective disorders
  • Alzheimer's disease
  • Anxiety
  • Depression
  • Estrogen receptor
  • Neuroprotection

ASJC Scopus subject areas

  • Endocrinology

Fingerprint Dive into the research topics of 'Estrogen action in mood and neurodegenerative disorders: Estrogenic compounds with selective properties - The next generation of therapeutics'. Together they form a unique fingerprint.

Cite this